101 results about "Ischaemia-reperfusion injury" patented technology

The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and / or preventing the onset and / or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia / reperfusion injury and cancer.

The present invention relates to compositions comprising a substantially pure compound represented by Structural Formula II:and methods of using such compounds to activate cytoprotective kinases.

The invention discloses an application of 3,5,4'-trihydroxy-stilbyl-3'-O-glucoside in the preparation of microcirculatory disturbance improvement medicines. The microcirculatory disturbance improvement medicines comprise 3,5,4'-trihydroxy-stilbyl-3'-O-glucoside as an effective active component, and one or more pharmaceutically acceptable auxiliary agents, especially gastrodin and / or water-soluble cyclodextrin derivatives and PEG400 and mannitol, wherein the structural formula of 3,5,4'-trihydroxy-stilbyl-3'-O-glucoside is shown in the specification. The microcirculatory disturbance improvement medicines treat 3,5,4'-trihydroxy-stilbyl-3'-O-glucoside as the effective active component, and are used for improving disturbances caused by cerebral microvascular damages and / or disturbances caused by ischemia reperfusion damages and / or disturbances caused by leukocyte adhesion damages, and / or disturbances caused by peroxides. Normal mice of Kunming species and artificially induced microcirculatory disturbance model mice undergo tail vein injection treatment, and results of the observation of arteriole and venule systole and capillary network under a microcirculatory microscope show that 3,5,4'-trihydroxy-stilbyl-3'-O-glucoside has an obvious expansion effect on the blood vessels of the normal mice, can obviously resist the reduction of the arteriole and venule systole and capillary network opening number of the microcirculatory disturbance model mice and can obviously resist the reduction of the blood flow speed.

The invention relates to use of ACY-1 as a biomarker for ischaemia-reperfusion injury.

The invention discloses a method for constructing a blood-spinal cord barrier (BSCB) oxygen-glucose deprivation / reoxygenation (OGD / R) injury model and an application thereof. Spinal cord derived microvascular endothelial cells were cultured in the upper chamber and mixed glial cells were cultured in the bottom chamber of the transwell culture system to construct the in vitro BSCB model. Microvascular endothelial cells in the upper chamber of transwell and mixed glial cells in the lower chamber of transwell interact with each other by secreting cytokines to form molecular membranes with good barrier function. OGD / R can effectively simulate the injury of BSCB induced by ischemia / reperfusion in vivo, and can more directly and accurately understand the changes of structure and function of BSCBafter ischemia / reperfusion injury. The results of the study have a high reference value, thus providing an effective basis for clinical study of BSCB.

The invention discloses a salicylamide derivative crystal and specifically discloses a compound shown in the formula 1. Under Cu-K alpha radiation, in the powder x-ray diffraction pattern represented by 2 theta angle, the compound has a diffraction peak at about 9.4 degrees. The invention also discloses a preparation method of the compound shown in the formula 1, a pharmaceutical composition containing the compound, and a use of the compound or its pharmaceutically acceptable salts, solvates, esters, prodrugs and isomers in preparation of drugs for treating or preventing cancers, inflammation, autoimmune disease, diabetes, diabetic complication, infection, cardiovascular diseases and ischemia-reperfusion injuries. The compound shown in the formula 1 has good drug properties.

Application of transfer RNA Molecules and their derived fragments for prevention or treatment of heart disease. The present invention provides a method of preventing or treating a subject suffering from heart diseases comprising administration of transfer RNA molecules and fragments derived from transfer RNA molecules or its functional variants or homologous to the subject, wherein the RNA molecules isolated from or derived from a plant of the genus Panax. The present invention also provides a pharmaceutical composition for the prevention or treatment of heart diseases comprising said effective amount of RNA molecule and a pharmaceutically tolerable vector, virus or excipient. The present invention provides a method for the prevention or treatment of a subject suffering from a heart disease. It is found that transfer RNA molecules from ginseng are particularly effective in the treatment of heart diseases, and also have a restorative effect on the myocardial cytoskeleton after ischemia-reperfusion injury.